Effect of personnalized anticancer chemotherapy based on high precision molecular diagnosis on locoregional and hematogenous dissemination of oral squamous cell carcinoma

Effect of personnalized anticancer chemotherapy based on high precision molecular diagnosis on locoregional and hematogenous dissemination of oral squamous cell carcinoma - Effect of personnalized anticancer chemotherapy on locoregional and hematogenous dissemination of oral squamous cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011800

Enrollment

140

Registered

2013-11-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Proven oral squamous cell carcinoma 2) To have a resectable lesion (T1-4a, N0-3) 3) No distant metastasis at first visit 4) ECOG performance status 0 or 1 5) No previous chemo- or radiotherapy. 6) WBC count 4,000/L, hemoglobin 10 g/L, platelet count 100,000/L, ALT and AST twice the upper limit of normal, bilirubin 1.5 and serum creatinine 1.2. 7) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) The possibility (will) of the pregnancy and nursing girl 2) Active multiple primary 3) Having a serious or life-threatening disease. 4) Having a mental disorder 5) Systemic steroid use 6) Having infection or fever up 7) Severe allergic reaction for any drugs 8) Edema (grade 2 and more) 9) Peripheral neuropathy (grade 2 and more)

Design outcomes

Primary

Measure	Time frame
Over all survival	—

Secondary

Measure	Time frame
Disease free survival, Time to distant metastasis, Adverse effects	—

Countries

Japan

Contacts

Public ContactHiroshi Kurita

Shinshu University School of Medicine Dentistry and Oral Surgery

hkurita@shinshu-u.ac.jp0263-37-2677

Outcome results